Last reviewed · How we verify

IDP-124 Lotion

Bausch Health Americas, Inc. · Phase 3 active Small molecule

IDP-124 is a topical lotion formulation combining calcipotriene and betamethasone dipropionate to reduce inflammation and normalize skin cell differentiation in psoriasis.

IDP-124 is a topical lotion formulation combining calcipotriene and betamethasone dipropionate to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis.

At a glance

Generic nameIDP-124 Lotion
SponsorBausch Health Americas, Inc.
Drug classTopical corticosteroid and vitamin D analog combination
TargetVitamin D receptor (VDR) and glucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Calcipotriene is a vitamin D3 analog that regulates keratinocyte proliferation and differentiation, while betamethasone dipropionate is a potent topical corticosteroid that suppresses inflammatory cytokines and immune cell infiltration. Together, these agents work synergistically to reduce erythema, scaling, and plaque formation characteristic of psoriasis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: